Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
Meijer D, Luiting HB, van Leeuwen PJ, Remmers S, Jansen BHE, Bodar YJL, Witteveen T, Schaake EE, van der Poel HG, Wondergem M, Busstra MB, Nieuwenhuijzen JA, Meijnen P, Brabander T, van Moorselaar RJA, Hendrikse NH, Oprea-Lager DE, Roobol MJ, Vis AN. Meijer D, et al. Among authors: jansen bhe. J Urol. 2021 Apr;205(4):1100-1109. doi: 10.1097/JU.0000000000001437. Epub 2020 Nov 18. J Urol. 2021. PMID: 33207138
Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.
Jansen BHE, van Leeuwen PJ, Wondergem M, van der Sluis TM, Nieuwenhuijzen JA, Knol RJJ, van Moorselaar RJA, van der Poel HG, Oprea-Lager DE, Vis AN. Jansen BHE, et al. Eur Urol Oncol. 2021 Oct;4(5):821-825. doi: 10.1016/j.euo.2020.01.002. Epub 2020 Feb 20. Eur Urol Oncol. 2021. PMID: 32088155
Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
Meijer D, Jansen BHE, Wondergem M, Bodar YJL, Srbljin S, Vellekoop AE, Keizer B, van der Zant FM, Hoekstra OS, Nieuwenhuijzen JA, Dahele M, Vis AN, Oprea-Lager DE. Meijer D, et al. Among authors: jansen bhe. PLoS One. 2020 Oct 6;15(10):e0239414. doi: 10.1371/journal.pone.0239414. eCollection 2020. PLoS One. 2020. PMID: 33021980 Free PMC article.
Reply by Authors.
Meijer D, Luiting HB, van Leeuwen PJ, Remmers S, Jansen BHE, Bodar YJL, Witteveen T, Schaake EE, van der Poel HG, Wondergem M, Busstra MB, Nieuwenhuijzen JA, Meijnen P, Brabander T, van Moorselaar RJA, Hendrikse NH, Oprea-Lager DE, Roobol MJ, Vis AN. Meijer D, et al. Among authors: jansen bhe. J Urol. 2021 Apr;205(4):1108-1109. doi: 10.1097/JU.0000000000001437.02. Epub 2021 Jan 25. J Urol. 2021. PMID: 33493004 No abstract available.
Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study.
Bodar YJL, Zwezerijnen BGJC, van der Voorn PJ, Jansen BHE, Smit RS, Kol SQ, Meijer D, de Bie K, Yaqub M, Windhorst BAD, Hendrikse HNH, Vis AN, Oprea-Lager DE. Bodar YJL, et al. Among authors: jansen bhe. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1731-1742. doi: 10.1007/s00259-021-05604-9. Epub 2021 Nov 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 34725727 Free PMC article.
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Jansen BHE, et al. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):509-520. doi: 10.1007/s00259-020-04974-w. Epub 2020 Aug 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 32789599 Free PMC article. Clinical Trial.
Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial.
Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, Boellaard R, Hendrikse NH, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Bodar YJL, et al. Among authors: jansen bhe. World J Urol. 2021 Jul;39(7):2439-2446. doi: 10.1007/s00345-020-03490-8. Epub 2020 Oct 20. World J Urol. 2021. PMID: 33079250 Free PMC article. Clinical Trial.
22 results